Upadacitinib significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis compared with placebo at week 14. Upadacitinib, sold under the brand name Rinvoq by Abbvie.
Upadacitinib, a Janus kinase inhibitor, has been shown to be effective in patients with ankylosing spondylitis. Researchers aimed to assess the efficacy and safety of upadacitinib in non-radiographic axial spondyloarthritis.
- Read more about Upadacitinib improves symptoms of axial spondyloarthritis patients
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/upadacitinib-improves-symptoms-of-axial-spondyloarthritis-patients
No comments:
Post a Comment